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extremely high-risk population, until we are able to overcome the
current limitations of contemporary medicine.
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Reply
We would like to thank Dr. Steg and Dr. Marques and colleagues
for their interest regarding our recent study (1). The more
widespread use of drug-eluting stents will have its implications in
perioperative management of patients undergoing noncardiac sur-
gery. Especially in the early phase after stent implantation, patients
are at increased risk, either owing to bleeding complications in
those who continued dual antiplatelet therapy or because of
in-stent thrombosis after antiplatelet discontinuation. These pa-
tients might be identified by troponin elevation and abrupt
ST-segment elevation in the territory of a recently implanted stent.
Although it is recommended to continue antiplatelet therapy in
this period during surgery, no convincing safety data exists.
Our report demonstrates that preoperative coronary revascular-
ization in 49 high-risk patients was not associated with an
improved outcome compared with medical therapy. Of this group,
a percutaneous coronary intervention was performed in 32 pa-
tients, and a drug-eluting stent was used in 30 patients. Of these
patients, a Q-wave myocardial infarction occurred in 11. Contin-
uous 12-lead electrocardiographic monitoring was performed in a
substudy for the detection of non–Q-wave ST-segment changes,
which may be present in up to 41% of patients and have prognostic
implications (2,3). Of the 11 patients with Q-wave myocardial
infarction, ST-segment elevation occurred in 7. The location of
ST-segment elevation corresponded to the recently stented coro-
nary artery territory in 5 of those 7 patients. Importantly, all
stented patients underwent surgery using dual antiplatelet therapy.
One might speculate that the increased thrombotic risk during
surgery as a result of cytokine response, catecholamine surge,
platelet activation, and reduced fibrinolytic activity can not be
prevented by dual platelet therapy.
How are we to treat these high-risk patients with a progressive
aortic aneurysm or critical limb ischemia? There are several
options. The suggestion of Dr. Marques and colleagues to refrain
from surgery if possible should indeed be considered. However, the
population studied had a clear indication for surgery. Because cardiac
outcome immediately after surgery was not improved by prophylactic
revascularization in this small study, a switch to postoperative coro-
nary revascularization could be considered in this high-risk popula-
tion. The indications for coronary revascularization in this population
after surgery are similar to the generally accepted indications for
revascularization provided by the American College of Cardiology/
American Heart Association guidelines (4). Furthermore, in selected
patients with an urgent need for surgery, endovascular repair with a
relatively low perioperative mortality rate is a promising option (5). In
a group of 2,368 high-risk patients based on clinical risk factors, 788
were scheduled for endovascular repair, with a 30-day mortality rate of
3.4%. If these promising results can be confirmed in patients with
high-risk coronary anatomy as well, endovascular repair should be
considered in this population as the treatment of choice.
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